• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

同步放化疗后晚期宫颈癌患者治疗失败的风险分层:优化治疗结果的另一种方法。

Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results.

作者信息

Liang Ji-An, Chen Shang-Wen, Chang Wei-Chun, Hung Yao-Ching, Yeh Lian-Shung, Yang Shih-Neng, Lin Fang-Jen

机构信息

Department of Radiation Therapy and Oncology, China Medical University Hospital, Taiwan.

出版信息

Clin Oncol (R Coll Radiol). 2008 Nov;20(9):683-90. doi: 10.1016/j.clon.2008.06.007. Epub 2008 Aug 3.

DOI:10.1016/j.clon.2008.06.007
PMID:18676129
Abstract

AIMS

To identify risk factors for disease-free survival (DFS) and para-aortic lymph node (PALN) metastasis in advanced cervical cancer patients after concurrent chemoradiotherapy (CCRT) using risk stratification.

MATERIALS AND METHODS

In total, 148 patients with stage IB2-IVA cervical cancer without PALN metastasis treated with a full course of CCRT were included for analysis. Radiotherapy consisted of external beam irradiation followed by four courses of high-dose rate intracavitary brachytherapy using 6.0 Gy to point A. Chemotherapy consisted of weekly cisplatin at a dose of 40mg/m(2) for a planned six cycles. Cox's proportional hazards model was used for risk stratification for DFS and PALN relapse-free survival.

RESULTS

Patients were divided into low- and high-risk groups. The low-risk group was composed of patients with stage IB-IIB disease without enlarged pelvic nodes, whereas the high-risk group was comprised of patients with stage IB2-IIB tumours with enlarged nodes or those with stage III-IVA disease. The 4-year DFS for the low- and high-risk groups was 83 and 52%, respectively (P=0.0001, relative risk 4.51, 95% confidence interval 1.3-10.7), whereas the 4-year PALN metastasis-free survival for the low- and high-risk groups was 92 and 61%, respectively (P=0.0003, relative risk 4.93, 95% confidence interval 1.2-12.5).

CONCLUSION

The risk of failure in advanced cervical cancer patients treated in the CCRT era can be predicted. For patients with high risk of PALN relapse, this study can provide patient selection criteria when considering prophylactic PALN irradiation.

摘要

目的

通过风险分层确定同步放化疗(CCRT)后晚期宫颈癌患者无病生存(DFS)和腹主动脉旁淋巴结(PALN)转移的风险因素。

材料与方法

共纳入148例接受全程CCRT治疗且无PALN转移的IB2-IVA期宫颈癌患者进行分析。放疗包括外照射,随后进行4个疗程的高剂量率腔内近距离放疗,A点剂量为6.0 Gy。化疗为每周一次顺铂,剂量为40mg/m²,计划进行6个周期。采用Cox比例风险模型对DFS和PALN无复发生存进行风险分层。

结果

患者分为低风险组和高风险组。低风险组由盆腔淋巴结未肿大的IB-IIB期疾病患者组成,而高风险组由淋巴结肿大的IB2-IIB期肿瘤患者或III-IVA期疾病患者组成。低风险组和高风险组的4年DFS分别为83%和52%(P=0.0001,相对风险4.51,95%置信区间1.3-10.7),而低风险组和高风险组的4年PALN无转移生存率分别为92%和61%(P=0.0003,相对风险4.93,95%置信区间1.2-12.5)。

结论

CCRT时代晚期宫颈癌患者的失败风险可以预测。对于PALN复发风险高的患者,本研究可为考虑预防性PALN照射时提供患者选择标准。

相似文献

1
Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results.同步放化疗后晚期宫颈癌患者治疗失败的风险分层:优化治疗结果的另一种方法。
Clin Oncol (R Coll Radiol). 2008 Nov;20(9):683-90. doi: 10.1016/j.clon.2008.06.007. Epub 2008 Aug 3.
2
Five years' experience treating locally advanced cervical cancer with concurrent chemoradiotherapy and high-dose-rate brachytherapy: results from a single institution.局部晚期宫颈癌同步放化疗联合高剂量率近距离放疗五年治疗经验:单机构研究结果
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):140-6. doi: 10.1016/j.ijrobp.2008.06.1920. Epub 2008 Oct 14.
3
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.同步化疗盆腔放疗与盆腔及腹主动脉旁放疗治疗高危宫颈癌的比较:放射肿瘤学组试验(RTOG)90-01的最新进展
J Clin Oncol. 2004 Mar 1;22(5):872-80. doi: 10.1200/JCO.2004.07.197.
4
Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion.术前同步放化疗用于治疗伴有宫旁组织近端浸润的IB2期、IIA期和IIB期子宫颈巨块型癌。
Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1508-15. doi: 10.1016/j.ijrobp.2008.03.054.
5
Concurrent chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors.高危因素子宫颈癌患者同步放化疗后序贯辅助化疗
Gynecol Oncol. 2007 Jan;104(1):58-63. doi: 10.1016/j.ygyno.2006.07.005. Epub 2006 Aug 17.
6
Cervical cancer: combined modality therapy.宫颈癌:综合治疗
Cancer J. 2001 Jul-Aug;7 Suppl 1:S47-50.
7
Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: a control cohort comparison with radiation alone on treatment outcome and complications.顺铂联合外照射放疗与高剂量率近距离放疗同步治疗晚期宫颈癌:与单纯放疗对照队列比较治疗结局和并发症
Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1370-7. doi: 10.1016/j.ijrobp.2006.07.004. Epub 2006 Sep 18.
8
Multi-institutional phase II clinical study of concurrent chemoradiotherapy for locally advanced cervical cancer in East and Southeast Asia.多机构合作的东亚和东南亚局部晚期宫颈癌同期放化疗 II 期临床研究。
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):751-7. doi: 10.1016/j.ijrobp.2009.06.011. Epub 2009 Oct 14.
9
A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.拓扑替康联合标准剂量顺铂及同步原发灶放疗用于局部晚期宫颈癌的可行性研究。
Gynecol Oncol. 2009 Jan;112(1):85-9. doi: 10.1016/j.ygyno.2008.09.029. Epub 2008 Nov 1.
10
Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer.使用高剂量率腔内近距离放射疗法对子宫颈癌进行同步放化疗。
Gynecol Oncol. 2005 Mar;96(3):665-70. doi: 10.1016/j.ygyno.2004.11.046.

引用本文的文献

1
Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.同期放化疗联合调强放疗后辅助化疗治疗高危局部晚期宫颈鳞癌:Ⅱ期研究。
BMC Cancer. 2022 Dec 20;22(1):1331. doi: 10.1186/s12885-022-10406-9.
2
The impact of para-aortic lymph node irradiation on disease-free survival in patients with cervical cancer: A systematic review and meta-analysis.腹主动脉旁淋巴结照射对宫颈癌患者无病生存期的影响:一项系统评价和荟萃分析。
Clin Transl Radiat Oncol. 2022 May 30;35:97-103. doi: 10.1016/j.ctro.2022.05.006. eCollection 2022 Jul.
3
Radiographic Number of Positive Pelvic Lymph Nodes as a Prognostic Factor in Cervical Cancer Treated With Definitive Concurrent Chemoradiotherapy or Intensity-Modulated Radiotherapy.
盆腔阳性淋巴结的影像学数量作为接受根治性同步放化疗或调强放疗的宫颈癌患者的预后因素
Front Oncol. 2018 Nov 30;8:546. doi: 10.3389/fonc.2018.00546. eCollection 2018.
4
Prognostic models for locally advanced cervical cancer: external validation of the published models.局部晚期宫颈癌的预后模型:已发表模型的外部验证
J Gynecol Oncol. 2017 Sep;28(5):e58. doi: 10.3802/jgo.2017.28.e58. Epub 2017 May 26.
5
Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience.半扩展野调强放射治疗联合顺铂同步治疗局部晚期宫颈癌患者的安全性和疗效:一项10年经验的观察性研究
Medicine (Baltimore). 2017 Mar;96(10):e6158. doi: 10.1097/MD.0000000000006158.
6
American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer.美国近距离放射治疗任务组报告:宫颈癌高剂量率近距离放射治疗临床结果的汇总分析。
Brachytherapy. 2017 Jan-Feb;16(1):22-43. doi: 10.1016/j.brachy.2016.03.008.
7
Optimal Extent of Prophylactic Irradiation of Paraaortic Lymph Nodes in Patients with Uterine Cervical Cancer.子宫颈癌患者腹主动脉旁淋巴结预防性照射的最佳范围
PLoS One. 2015 Dec 14;10(12):e0145158. doi: 10.1371/journal.pone.0145158. eCollection 2015.